Ligand Pharmaceuticals (LGND) Research & Development (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Research & Development data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 95.71% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.2 million (down 49.27% YoY), and the FY2025 full-year result was $81.2 million, up 278.91% from the prior year.
• Research & Development retreated to $2.1 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $50.1 million in Q1 2025 to a low of $2.1 million in Q1 2026.
• A 5-year average of $9.7 million and a median of $6.6 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 738.8% in 2025 and plunged 95.71% in 2026, its largest moves.
• Tracing LGND's Research & Development over 5 years: stood at $9.2 million in 2022, then plunged by 40.33% to $5.5 million in 2023, then fell by 19.37% to $4.4 million in 2024, then decreased by 20.66% to $3.5 million in 2025, then plunged by 38.82% to $2.1 million in 2026.
• Business Quant data shows LGND's Research & Development at $2.1 million in Q1 2026, $3.5 million in Q4 2025, and $21.0 million in Q3 2025.